Thread by @RitaINdeFaria

Which @ISPORorg #ISPOREurope session would you like a live twitter thread tomorrow? You can help me choose by voting 🗳️😀

https://twitter.com/RitaINdeFaria/status/1328294629511467010

One option is IP6: How Should Pharmaceutical Companies and Patients Served By Health Systems Share the Value Generated By New Medicines? with Danny Palnoch from @NHSEngland, @bs_woods from @CHEyork, Jens Grueger from @UW_Pharmacy and Patricia Danzon from @Wharton #ISPOREurope

Or IP8: Integrating Patient Preference into Health Technology Assessment- Can Patient Preferences be Incorporated into the ICER? w/ Esther de Bekker-Grob @erasmusuni, Kevin Marsh @evideraglobal, Mendwas Dzingina @pfizer & @JacolineBouvy at @NICEComms
#ISPOREurope

Or SP2: Is Credible, Robust Real-World Evidence Just a Myth? with Anja Schiel at Norwegian Medicines Agency, Xavier Kurz at @EMA_News, Nancy A Dreyer from @IQVIA_global and Robert Golub from @JAMA_current
#ISPOREurope

Or W2: Methodological and Normative Issues Arising in Recently Updated National Guidelines for Economic Evaluation, with @mfosoares and @MJSculpher from @CHEyork, Conor Teljeur at @HIQA and Ian Watson at @NICEComms
#ISPOREurope